Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive WF10 with capecitabine in unresectable pancreatic cancer
2005-003553-27Phase 2Completed
- Sponsor
- Miravo Healthcare
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tetrachlorodecaoxide in pancreatic cancer (PC), sponsored by Miravo Healthcare. Primary endpoint: Survival at 6 months. Started May 2006; status: completed.
02
Drugs
tetrachlorodecaoxide
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2005-003553-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003553-27.